medroxyprogesterone / Generic mfg. - LARVOL DELTA

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: University College, London

New P3 trial • Endometrial Cancer • Oncology • Solid Tumor • Uterine Cancer

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer (clinicaltrials.gov) - P=N/A | N=16 | Recruiting | Sponsor: Peking University People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Endometrial Cancer • Oncology • Solid Tumor

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Bayer | N=109 ➔ 0 | Terminated ➔ Withdrawn

Enrollment change • Trial withdrawal

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=109 | Terminated | Sponsor: Bayer | N=207 ➔ 109 | Trial completion date: Nov 2027 ➔ Jun 2026 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2027 ➔ Jun 2026; Bayer terminated study 22923 due to enrollment challenges, including difficulties identifying eligible patients, participation requirements, and site burden. The decision was unrelated to safety and does not change Mirena's benefit-risk profile.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Evaluating progestin-primed and GnRH antagonist ovarian stimulation protocols in PGT-A cycles: implications for clinical practice. (PubMed, BMC Pregnancy Childbirth) - "PPOS and GnRH antagonist protocols yield comparable embryological and clinical outcomes in PGT-A cycles, including in advanced maternal age and diminished ovarian reserve subgroups. With its shorter stimulation duration and cost-effectiveness, PPOS is a valid alternative when fresh transfer is not planned."

Journal

Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov) - P=N/A | N=320 | Recruiting | Sponsor: Weill Medical College of Cornell University | Not yet recruiting ➔ Recruiting

Enrollment open

Association of High-Sensitivity C-Reactive Protein With Metabolic but Not Endocrine Parameters in Women With Polycystic Ovary Syndrome (ASRI 2026) - "After 1 year of treatment, no significant difference in hs-CRP levels was observed between the oral contraceptive group (drospirenone/ethinyl estradiol; Yaz®, Bayer AG, Germany) and the cyclic progestin group (medroxyprogesterone acetate 10 mg; Provera®, Pfizer Italia S.r.l., Italy). In women with PCOS, hs-CRP levels were significantly associated with metabolic parameters but not with endocrine parameters, including hyperandrogenemia. In women with PCOS, hs-CRP levels were significantly associated with metabolic parameters but not with endocrine parameters, including hyperandrogenemia. These findings suggest that hs-CRP may serve as a potential marker of metabolic risk in this population. Further prospective studies are warranted to clarify its clinical implications."

Clinical • Diabetes • Endocrine Disorders • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Polyendocrine Metabolic Ovarian Syndrome • Type 2 Diabetes Mellitus • CRP

RESToRE: Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (clinicaltrials.gov) - P4 | N=96 | Completed | Sponsor: University of British Columbia | Active, not recruiting ➔ Completed | N=250 ➔ 96

Enrollment change • Trial completion • Endometrial Cancer • Oncology • Solid Tumor • Uterine Cancer

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=207 | Recruiting | Sponsor: Bayer | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date

The Progesterone Challenge Test as a Functional Biomarker of Endometrial Cancer Risk: Results from a Prospective Feasibility Study. (PubMed, Cancer Prev Res (Phila)) - P4 | "Asymptomatic postmenopausal participants, defined by the absence of vaginal bleeding, with body mass index ≥34.9 kg/m² and an intact uterus, completed a 10-day course of oral medroxyprogesterone acetate (MPA) 10 mg daily. The PCT was feasible, well-tolerated, and acceptable among higher-risk postmenopausal individuals, supporting its use as a physiologic, functional biomarker of endometrial responsiveness. These findings provide early evidence for a scalable, low-cost strategy to identify individuals likely to benefit from targeted EC prevention."

Biomarker • Journal • Endometrial Cancer • Genetic Disorders • Obesity • Oncology • Solid Tumor

Development of institutional guidelines for menstrual suppression and abnormal uterine bleeding in patients undergoing intensive chemotherapy for hematologic malignancies. (PubMed, Support Care Cancer) - "Based on data from the retrospective chart review, an institutional guideline was created, including recommendations for patients to receive a 3-month formulation of leuprolide acetate with concomitant oral medroxyprogesterone at 20 mg/day for prevention of uterine bleeding. Further prospective studies are needed to determine optimal strategies for prevention and treatment of uterine bleeding in this patient population."

Journal • Retrospective data • Hematological Disorders • Hematological Malignancies • Oncology • Women's Health

Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol. (PubMed, Hum Fertil (Camb)) - "This study evaluates the efficacy and cost-effectiveness of progestin-primed ovarian stimulation (PPOS) using oral medroxyprogesterone acetate in fertility preservation cycles...The PPOS protocol was considerably more cost-effective, by achieving a 98.06% cost reduction (medroxyprogesterone acetate, mean £4.38 [SD, £1.10] vs cetrorelix acetate £226.2 [SD £64.36], p= <0.0001. PPOS is a practical, cost-effective strategy for fertility preservation. Its appeal lies in its patient-centric focus, with a less invasive injection-based administration, while maintaining comparable effectiveness and significant cost reduction compared with the GnRH antagonist ovarian stimulation protocol."

Clinical • HEOR • Journal • Retrospective data

Progestin-suppressed in vitro fertilization cycles yield similar outcomes to traditional protocols in patients with diminished ovarian reserve. (PubMed, F S Rep) - "Administration of 10 mg/day of oral medroxyprogesterone acetate (MPA) beginning on stimulation day 1, compared with standard gonadotropin-releasing hormone antagonist and microdose leuprolide flare protocols. In multivariable models, the treatment group was not associated with the likelihood of having an embryo available for transfer (odds ratio 1.26, 95% confidence interval 0.74-1.53) or clinical pregnancy (odds ratio 0.98, 95% confidence interval 0.50-1.95). The progestin-suppressed IVF protocol provides similar reproductive outcomes in patients with diminished ovarian reserve, with the advantages of fewer monitoring visits, reduced injections, and lower medication costs."

Journal • Preclinical • Gynecology

Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov) - P=N/A | N=320 | Not yet recruiting | Sponsor: Weill Medical College of Cornell University | Initiation date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2028 ➔ Sep 2029

Trial initiation date • Trial primary completion date

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=207 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2027 ➔ May 2027 | Trial primary completion date: Jan 2027 ➔ May 2027

Enrollment open • Trial completion date • Trial primary completion date

Medroxyprogesterone Acetate Inhibits Tumorigenesis in Mouse Models of Oviductal High-Grade Serous Carcinoma. (PubMed, Cancers (Basel)) - "These findings demonstrate that a synthetic progestin, specifically MPA, confers robust protection against HGSC development, while a combination including E2 (E2 + P4) increases risk. This work also illustrates how HGSC GEMMs can be used to compare the chemo-preventive effects of various synthetic progestins on HGSC development in order to prioritize the most effective ones for use in preventing HGSC in both general and high-risk populations."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • NF1 • RB1 • TP53

SUNFLOWER: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (clinicaltrials.gov) - P3 | N=207 | Not yet recruiting | Sponsor: Bayer | N=300 ➔ 207

Enrollment change

Hormonal Therapy and Hepatic Risk: A Case Report of Progestin-Induced Cholestatic Liver Injury (ACG 2025) - "Here we present a case of a postmenopausal woman with end-stage liver disease and abnormal uterine bleeding requiring progestin therapy, who subsequently sustained an unusual pattern of liver injury.Case Description/ The patient is a 64-year-old female with known HIV on Biktarvy, CKD, MASH cirrhosis decompensated by ascites, non-bleeding esophageal varices, and hepatic encephalopathy with prior listing for dual kidney/liver transplant, who was admitted for postmenopausal bleeding in the setting of new cervical/uterine mass...She was started on Provera with good effect in controlling her bleeding, however her liver enzymes, bilirubin in particular, acutely worsened; AST/ALT 91/31, ALP 143 total bilirubin 19...Clinicians should maintain a high level of suspicion when evaluating patients on hormonal therapy with acutely worsening liver enzymes, regardless of the pattern of injury. It is critical to consider various differentials, in order to optimize treatment in medically..."

Case report • Clinical • Chronic Kidney Disease • CNS Disorders • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Liver Failure • Long-acting Reversible Contraceptives • Metabolic Dysfunction-Associated Steatohepatitis • Women's Health

The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "No statistically significant changes were found in homocysteine or IL-6 levels. While MPA/CEE therapy significantly reduces CRP and fibrinogen, key inflammatory and cardiovascular risk markers, these findings suggest a notable protective effect of oral MPA/CEE on inflammation, highlighting the need for individualized therapeutic strategies based on patient risk profiles."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Inflammation • CRP • IL6

Impact of postoperative intrauterine therapies on IVF outcomes in patients with Asherman's Syndrome (ESGE 2025) - "Following catheter removal, a copper intrauterine device (IUD) was inserted, and patients received oral estradiol valerate (12–18 mg/day for 28 days) and oral medroxyprogesterone acetate (10 mg/day for the last 7 days). The complete resolution of menstrual disturbances and promising pregnancy results in both patient groups support the integration of tailored intrauterine therapies into routine clinical practice for endometrial rehabilitation prior to IVF. Further large-scale studies are warranted."

Clinical • Gynecology • Infertility • Long-acting Reversible Contraceptives • Mood Disorders • Pediatrics • Sexual Disorders • Women's Health

Endometrial regenerative therapy in patients with thin endometrium: A prospective case series (ESGE 2025) - "Postoperatively, all patients received standardized hormonal therapy with oral estradiol valerate (12–18 mg/day for 28 days) and oral medroxyprogesterone acetate (10 mg/day during the final 7 days) to induce withdrawal bleeding. The high clinical pregnancy and live birth rates observed in this cohort support the potential efficacy of this protocol. These findings underscore the need for further controlled trials to standardize treatment strategies and identify patients who may benefit most from regenerative intrauterine interventions."

Clinical • Gynecology • Infectious Disease

Effectiveness of combined clindamycin phosphate and medroxyprogesterone acetate tablets in treatment of endometritis. (PubMed, Afr J Reprod Health) - "No severe adverse reactions were observed. These findings suggest that the combination of CPT and MAT is more effective than CPT alone in alleviating symptoms, reducing inflammation, and promoting menstrual normalization in patients with endometritis."

Clinical • Journal • Endometriosis • Gynecology • Inflammation • Musculoskeletal Pain • Pain • IL4 • MMP2 • MMP9 • TGFB1 • TNFA • VCAM1

An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera (clinicaltrials.gov) - P1/2 | N=200 | Recruiting | Sponsor: Urmila DIwekar | Not yet recruiting ➔ Recruiting

Enrollment open • Infertility • Sexual Disorders

Intrauterine Stent Placement Following Hysteroscopic Septum Resection (clinicaltrials.gov) - P=N/A | N=320 | Not yet recruiting | Sponsor: Weill Medical College of Cornell University | Initiation date: Jun 2025 ➔ Oct 2025

Trial initiation date

Long-term disease-free survival after bilateral video-assisted thoracoscopic resection of multiple pulmonary metastases from endometrial stromal sarcoma: An 8-year follow-up case report. (PubMed, Gynecol Oncol Rep) - "The patient received oral medroxyprogesterone acetate for five years...She remains disease-free a total of eight years after metastasectomy. Complete resection of bilateral multiple pulmonary metastases from LG-ESS, combined with hormonal therapy, can achieve durable long-term disease control in carefully selected patients."

Journal • Video • Cardiovascular • Gynecology • Hematological Disorders • Oncology • Sarcoma • Solid Tumor • Subarachnoid Hemorrhage • Uterine Cancer • Vascular Neurology • MME • PGR